» Articles » PMID: 11983916

Characterization of the C-MYC-regulated Transcriptome by SAGE: Identification and Analysis of C-MYC Target Genes

Overview
Specialty Science
Date 2002 May 2
PMID 11983916
Citations 165
Authors
Affiliations
Soon will be listed here.
Abstract

To identify target genes of the oncogenic transcription factor c-MYC, serial analysis of gene expression (SAGE) was performed after adenoviral expression of c-MYC in primary human umbilical vein endothelial cells: 216 different SAGE tags, corresponding to unique mRNAs, were induced, whereas 260 tags were repressed after c-MYC expression (P < 0.05). The induction of 53 genes was confirmed by using microarray analysis and quantitative real-time PCR: among these genes was MetAP2/p67, which encodes an activator of translational initiation and represents a validated target for inhibition of neovascularization. Furthermore, c-MYC induced the cell cycle regulatory genes CDC2-L1, Cyclin E binding protein 1, and Cyclin B1. The DNA repair genes BRCA1, MSH2, and APEX were induced by c-MYC, suggesting that c-MYC couples DNA replication to processes preserving the integrity of the genome. MNT, a MAX-binding antagonist of c-MYC function, was up-regulated, implying a negative feedback loop. In vivo promoter occupancy by c-MYC was detected by chromatin immunoprecipitation for CDK4, Prohibitin, MNT, Cyclin B1, and Cyclin E binding protein 1, showing that these genes are direct c-MYC targets. The c-MYC-regulated genes/tags identified here will help to define the set of bona fide c-MYC targets and may have potential therapeutic value for inhibition of cancer cell proliferation, tumor-vascularization, and restenosis.

Citing Articles

CTSO and HLA-DQA1 as biomarkers in sepsis-associated ARDS: insights from RNA sequencing and immune infiltration analysis.

Shen Y, Yao Y, Li H, Li Y, Hu Y BMC Infect Dis. 2025; 25(1):326.

PMID: 40055592 PMC: 11887161. DOI: 10.1186/s12879-025-10726-8.


An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth.

Li M, Li J, He C, Jiang G, Ma D, Guan H J Biol Chem. 2024; 301(1):108030.

PMID: 39615685 PMC: 11730240. DOI: 10.1016/j.jbc.2024.108030.


HSPA12A promotes c-Myc lactylation-mediated proliferation of tubular epithelial cells to facilitate renal functional recovery from kidney ischemia/reperfusion injury.

Li Y, Min X, Zhang X, Cao X, Kong Q, Mao Q Cell Mol Life Sci. 2024; 81(1):404.

PMID: 39277835 PMC: 11402889. DOI: 10.1007/s00018-024-05427-5.


Immune evasion: An imperative and consequence of MYC deregulation.

Krenz B, Lee J, Kannan T, Eilers M Mol Oncol. 2024; 18(10):2338-2355.

PMID: 38957016 PMC: 11459038. DOI: 10.1002/1878-0261.13695.


Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.

Hamilton G, Stickler S, Rath B Curr Cancer Drug Targets. 2024; 24(9):930-940.

PMID: 38275056 DOI: 10.2174/0115680096272757231211113206.


References
1.
Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M . Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001; 15(16):2042-7. PMC: 312761. DOI: 10.1101/gad.907901. View

2.
Soucie E, Annis M, Sedivy J, Filmus J, Leber B, Andrews D . Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol Cell Biol. 2001; 21(14):4725-36. PMC: 87151. DOI: 10.1128/MCB.21.14.4725-4736.2001. View

3.
Yang X, Ogryzko V, Nishikawa J, Howard B, Nakatani Y . A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 1996; 382(6589):319-24. DOI: 10.1038/382319a0. View

4.
Berns K, Hijmans E, Bernards R . Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene. 1997; 15(11):1347-56. DOI: 10.1038/sj.onc.1201280. View

5.
Nijtmans L, de Jong L, Artal Sanz M, Coates P, Berden J, Back J . Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000; 19(11):2444-51. PMC: 212747. DOI: 10.1093/emboj/19.11.2444. View